Author Question: Critics complain that pharmaceutical research budgets emphasize non-debilitating conditions common ... (Read 51 times)

K@

  • Hero Member
  • *****
  • Posts: 608
Critics complain that pharmaceutical research budgets emphasize non-debilitating conditions common in developed countries rather than life-threatening diseases common in developing countries.
 
  People answering this criticism have contended that ________.
  A) correction of developed country conditions, such as balding, are necessary to stimulate developing country innovations that push global economic growth
  B) very small portions of research budgets actually target these non-debilitating conditions
  C) by being located almost entirely in developed countries, pharmaceutical companies lack access to locations where they can study diseases such as malaria and sleeping sickness
  D) pharmaceutical companies cannot recoup expenses for research on some of the developing country problems, so governmental research centers and nonprofit foundations should handle this research

Question 2

Which term refers to a firm building and operating a facility before transferring ownership of the facility to another party?
 
  A) FDI
  B) B-O-T project
  C) turnkey project
  D) greenfield strategy


bigcheese9

  • Sr. Member
  • ****
  • Posts: 333
Answer to Question 1

D

Answer to Question 2

B



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Since 1988, the CDC has reported a 99% reduction in bacterial meningitis caused by Haemophilus influenzae, due to the introduction of the vaccine against it.

Did you know?

Eating food that has been cooked with poppy seeds may cause you to fail a drug screening test, because the seeds contain enough opiate alkaloids to register as a positive.

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

Illicit drug use costs the United States approximately $181 billion every year.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library